Big Flats NY – XGen Pharmaceuticals DJB Inc. announced today the relaunch of Ibuprofen Lysine injection.  Ibprofen Lysine injection is therapeutically equivalent to Recordati Rare Diseases’ NeoProfen® Injection.

Ibuprofen Lysine Injection is indicated to close a clinically significant patent ductus arteriosus (PDA), an abnormal opening between the aorta and the pulmonary artery. Ibuprofen Lysine treats premature infants weighing between 500 and 1500 g who are no more than 32 weeks gestational age when usual medical management is ineffective.